Bristol Myers Squibb (CELG-RI) FCF Margin (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly FCF Margin of 23.8% for Q2 2026, down 518.0% year-over-year from 5.69% in Q2 2025, and up 261.26% quarter-over-quarter from 6.59% in Q1 2026.
Bristol Myers Squibb (CELG-RI) FCF Margin (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported FCF Margin for 18 consecutive years, with 23.8% the latest figure, recorded in Q2 2026.
- In Q2 2026, FCF Margin fell 518.0% year-over-year to 23.8%; the TTM figure through Jun 2026 stood at 23.26% (down 730.0% YoY), while the FY2025 annual figure was 26.65%, down 221.0% from the prior year.
- FCF Margin rose to 23.8% in Q2 2026 per CELG-RI's latest filing, from 6.59% in the prior quarter.
- Across five years, FCF Margin topped out at 49.02% in Q3 2025 and bottomed at 6.59% in Q1 2026.
- Historically, FCF Margin has averaged 26.03% across 5 years, with a median of 24.88% in 2026.
- On a YoY basis, FCF Margin climbed as much as 1207 bps in 2025 and fell as far as 2007 bps in 2025.
- Bristol Myers Squibb's FCF Margin stood at 25.95% in 2022, then soared by 32 bps to 34.17% in 2023, then slipped by 4 bps to 32.9% in 2024, then sank by 61 bps to 12.83% in 2025, then surged by 86 bps to 23.8% in 2026.
- Business Quant data shows CELG-RI's FCF Margin at 23.8% in Q2 2026, 6.59% in Q1 2026, and 12.83% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.90 Bn | 629.14 Bn | 17.26 Bn | 28.82% |
| 2 | AbbVie | 467.27 Bn | 460.70 Bn | 12.70 Bn | 18.33% |
| 3 | Merck | 376.18 Bn | 369.04 Bn | 12.21 Bn | 26.96% |
| 4 | Novartis Ag | 300.31 Bn | 292.62 Bn | 11.24 Bn | 38.60% |
| 5 | Astrazeneca | 256.63 Bn | 251.73 Bn | 12.86 Bn | -12.07% |
| 6 | Amgen | 235.80 Bn | 221.81 Bn | 7.24 Bn | 34.70% |
| 7 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | 44.00% |
| 8 | Pfizer | 160.71 Bn | 149.01 Bn | 10.94 Bn | 2.01% |
| 9 | Gsk | 105.41 Bn | 101.24 Bn | 8.24 Bn | 3.90% |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn | 23.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.80% |
| Mar 31, 2026 | 6.59% |
| Dec 31, 2025 | 12.83% |
| Sep 30, 2025 | 49.02% |
| Jun 30, 2025 | 28.98% |
| Mar 31, 2025 | 15.12% |
| Dec 31, 2024 | 32.90% |
| Sep 30, 2024 | 44.29% |
| Jun 30, 2024 | 16.92% |
| Mar 31, 2024 | 21.49% |
| Dec 31, 2023 | 34.17% |
| Sep 30, 2023 | 40.21% |
| Jun 30, 2023 | 14.50% |
| Mar 31, 2023 | 23.75% |
| Dec 31, 2022 | 25.95% |
| Sep 30, 2022 | 30.67% |
| Jun 30, 2022 | 16.73% |
| Mar 31, 2022 | 30.55% |
| Dec 31, 2021 | 31.18% |
| Sep 30, 2021 | 42.98% |